Hyperserotonemia and amine metabolites in autistic and retarded children.
about
Nanostructure-initiator mass spectrometry (NIMS) imaging of brain cholesterol metabolites in Smith-Lemli-Opitz syndromeStatistical distribution of blood serotonin as a predictor of early autistic brain abnormalities.Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatmentsMonoamines (serotonin and catecholamines) and their derivatives in infantile autism: age-related changes and drug effectsHyperserotoninemia and altered immunity in autismThe serotonin system in autism spectrum disorder: From biomarker to animal modelsThe Gut Microbiota and Autism Spectrum Disorders.N-ethylmaleimide-sensitive factor interacts with the serotonin transporter and modulates its trafficking: implications for pathophysiology in autismLinks between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence.New directions in the treatment of autism spectrum disorders from animal model research.5-Hydroxytryptamine (5-HT) cellular sequestration during chronic exposure delays 5-HT3 receptor resensitization due to its subsequent release.Autism: review of neurochemical investigation.Selective Serotonin Reuptake Inhibitor Use during Pregnancy and the Risk of Autism Spectrum Disorders: A ReviewDiagnostic and assessment issues related to pharmacotherapy for children and adolescents with autism.Lrp5 and bone formation : A serotonin-dependent pathway.Dystrophic serotonin axons in postmortem brains from young autism patients.The hyperserotonemia of autism.Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy.Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach.Maternal SSRI discontinuation, use, psychiatric disorder and the risk of autism in children: a meta-analysis of cohort studies.Microbiome and nutrition in autism spectrum disorder: current knowledge and research needs.Integrins in synapse regulation.Halopemide, a new psychotropic agent. Cerebral distribution and receptor interactions.Clinical effects of fenfluramine on children with autism: a review of the research.Pharmacologic treatment of psychiatric and neurodevelopmental disorders in children and adolescents (Part 3).Overview of selected basic research in autism.The functional neuroanatomy of infantile autism.Origin of the blood hyperserotonemia of autism.Platelet size, number, and serotonin content in blood of autistic, childhood schizophrenic, and normal children.Fenfluramine treatment of twenty children with autism.Elevated blood serotonin in autistic probands and their first-degree relatives.Platelet serotonin, a possible marker for familial autism.Whole blood serotonin and tryptophan in autism: temporal stability and the effects of medication.Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.Clinical and genetic relationships between autism-pervasive developmental disorder and Tourette syndrome: a study of 19 cases.The psychopharmacology of autism and related disorders.Searching for very early precursors of autism spectrum disorders: the Hamamatsu Birth Cohort for Mothers and Children (HBC).Risperidone in the treatment of pervasive developmental disorder.Relationships of whole blood serotonin and plasma norepinephrine within families.A controlled crossover trial of fenfluramine in autism.
P2860
Q24633389-27043D9D-777D-48BD-AA4C-803E3124BC36Q24811773-4D5DB363-6FA7-4679-8D02-6866D517672CQ26850307-1ED99674-7C4E-4EBF-A5C4-DD110B6515DCQ28188009-A151A2E5-6664-4841-AF4D-0F8EBD667E66Q28307190-BAA88B6E-927F-46DD-B717-447048E123F1Q28391614-94B36161-C332-48BA-9BCB-27368D56E309Q33613009-7A9042B4-0BD3-47A1-9C9D-7C33F6419E21Q33617477-A1AB0049-1375-426A-9834-31134607879CQ34047430-0FDD9D8F-35D5-4501-9143-8E261E4EFED5Q34267391-9B050D14-B5EC-4C64-8839-549E515BA854Q34509740-BF12FDAC-5017-440E-BDEA-A682909D277FQ36605375-5EBB0650-5E94-4F9D-8543-BF29738562EAQ37032700-1210BEC4-9279-450A-9295-B91AC7E31F3BQ37523280-5B9FBB8C-D6C9-4A52-8713-6D33712680BBQ37730895-817830CF-B055-4494-A287-66F3BA51DBBCQ37929093-2EFB3528-D499-4A3B-B5A0-AFD4E1A24498Q38004443-1E677D18-5CAD-4488-BBA3-C8EE0E454E60Q38089714-369766C2-EE42-45EB-BE89-C6B4DC97CAC6Q38268023-F6C86510-D339-4B2B-962A-ADD402ACAECDQ38653394-2D53C1CD-B200-486C-BC62-12B9667E1742Q38793435-41F35DA9-0CE0-4F73-997E-68470EE2BF3DQ38998162-CBFC6068-B566-41B5-A199-28E235D63225Q39493424-090414F0-7BC6-4985-BE2E-F1249235EE44Q39518682-60EEF987-FF30-448F-8CB6-9A2B50EB770FQ39727717-0DBF0CFD-E24A-41D0-A72B-87DA8EB703BCQ40253031-1A6BD6CF-3513-498A-83F0-A816ABA82F00Q40273261-A9FF6B20-CEC2-40BC-B837-40A9C3F446BAQ41069018-D0186B89-E1DD-4AA7-9306-4FDDF49E0809Q41437189-E97634F1-2A6F-4501-A63D-E5E6E95A631BQ42193115-DFE0FCEB-4A14-4451-BFA9-FCB4053A563EQ44001793-6C3CAC7C-A2CA-42B8-A06B-C93AEAD7C90DQ44362988-CF2BC158-7760-4B6D-98C7-F54B37F92018Q45002776-D044447E-1956-4C97-A191-C30E765CEBC8Q46111793-986B9DBD-2F86-4165-9A5F-D03261123FBFQ47573239-EBD4C3F2-308A-48A0-BF6A-93FA879AAF57Q50303371-AD3A8B5C-DE0D-4B78-83F5-238F32AA0771Q50303588-66471FCF-D191-43FC-B559-15FBFE7DBD83Q50304209-3A050C26-8B01-441D-B7C4-636D74517AB5Q50306474-1516791A-FD59-4E38-9307-7EA68E8B0687Q50306683-49E35BDD-E02C-4A37-A72F-2220B5918153
P2860
Hyperserotonemia and amine metabolites in autistic and retarded children.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年学术文章
@wuu
1977年学术文章
@zh-cn
1977年学术文章
@zh-hans
1977年学术文章
@zh-my
1977年学术文章
@zh-sg
1977年學術文章
@yue
1977年學術文章
@zh
1977年學術文章
@zh-hant
name
Hyperserotonemia and amine metabolites in autistic and retarded children.
@en
Hyperserotonemia and amine metabolites in autistic and retarded children.
@nl
type
label
Hyperserotonemia and amine metabolites in autistic and retarded children.
@en
Hyperserotonemia and amine metabolites in autistic and retarded children.
@nl
prefLabel
Hyperserotonemia and amine metabolites in autistic and retarded children.
@en
Hyperserotonemia and amine metabolites in autistic and retarded children.
@nl
P2093
P1433
P1476
Hyperserotonemia and amine metabolites in autistic and retarded children.
@en
P2093
P304
P356
10.1001/ARCHPSYC.1977.01770170031002
P407
P577
1977-05-01T00:00:00Z